Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAGE-718 with ketamine challenge in healthy volunteers
NCT03844906Phase 1Completed
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- Dec 2018
- Primary completion
- Mar 2019
- Modality
- Allosteric Modulators, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing SAGE-718 with Placebo (2 arms). Primary endpoints: Changes in Electrophysiological Parameters Pre- and Post-ketamine Infusion at Day 11 and Auditory-Evoked Potentials at Day 11. Started Dec 2018; status: completed.
02
Drugs
dalzanemdor
Beyond the preview
Go deeper on NCT03844906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03844906.